Literature DB >> 34636058

Neuroblastoma-Telomere maintenance, deregulated signaling transduction and beyond.

Sabine A Stainczyk1,2, Frank Westermann1,2.   

Abstract

The childhood malignancy neuroblastoma belongs to the group of embryonal tumors and originates from progenitor cells of the sympathoadrenal lineage. Treatment options for children with high-risk and relapsed disease are still very limited. In recent years, an ever-growing molecular diversity was identified using (epi)-genetic profiling of neuroblastoma tumors, indicating that molecularly targeted therapies could be a promising therapeutic option. In this review article, we summarize the various molecular subtypes and genetic events associated with neuroblastoma and describe recent advances in targeted therapies. We lay a strong emphasis on the importance of telomere maintenance mechanisms for understanding tumor progression and risk classification of neuroblastoma.
© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Entities:  

Keywords:  (epi)-genetics; neuroblastoma; risk stratification; targeted therapies; telomere maintenance

Mesh:

Substances:

Year:  2021        PMID: 34636058     DOI: 10.1002/ijc.33839

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  6'-O-Galloylpaeoniflorin Exerts Inhibitory Bioactivities in Human Neuroblastoma Cells via Modulating AMPK/miR-489/XIAP Pathway.

Authors:  Lijun Zhou; Aiwu Li; Qiangye Zhang
Journal:  Biomed Res Int       Date:  2022-05-05       Impact factor: 3.246

Review 2.  Chromosome Imbalances in Neuroblastoma-Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the Future.

Authors:  Jikui Guan; Bengt Hallberg; Ruth H Palmer
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

Review 3.  Emerging Role and Mechanism of circRNAs in Pediatric Malignant Solid Tumors.

Authors:  Qiyang Shen; Xingyu Liu; Wei Li; Xu Zhao; Tao Li; Kai Zhou; Jianfeng Zhou
Journal:  Front Genet       Date:  2022-01-18       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.